We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current NAMSW market cap is 802.44M. The company's latest EPS is EUR -2.1455 and P/E is -10.30.
| Quarter End | |
|---|---|
| EUR (€) | |
| Total Revenue | |
| Operating Income | |
| Net Income |
| Year End 31 December 2023 | 2023 |
|---|---|
| EUR (€) | |
| Total Revenue | 14.09M |
| Operating Income | -182.69M |
| Net Income | -176.94M |
| Quarter End | |
|---|---|
| EUR (€) | |
| Total Assets | |
| Total Liabilities | |
| Total Equity |
| Year End 31 December 2023 | 2023 |
|---|---|
| EUR (€) | |
| Total Assets | 347.1M |
| Total Liabilities | 58.7M |
| Total Equity | 288.39M |
| Market Cap | 802.44M |
| Price to Earnings Ratio | -10.30 |
| Price to Sales Ratio | 129.26 |
| Price to Cash Ratio | 5.35 |
| Price to Book Ratio | 6.32 |
| Dividend Yield | - |
| Shares Outstanding | 82.47M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 14 (100%) |
| Company Name | NewAmsterdam Pharma Company NV |
| Address |
gooimeer 2-35 naarden, north holland 1411 DC |
| Website | https://www.newamsterdampharma.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
